Biocon Mycophenolic Acid gets USFDA okay
New Delhi: Biocon Pharma Limited, a subsidiary of Biocon Limited has received approval from the U S Food and Drug Administration (USFDA) for Mycophenolic Acid.
This product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. It is available in 180mg and 360mg strengths.
"This approval further adds to Biocon's portfolio of vertically integrated complex drug products," the company said in a BSE filing.
Biocon Limited is an innovation-led global biopharmaceuticals company headquartered in Bangalore. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.
Read also: Biocon Biologics, Viatris to offer Insulin Glargine by Walgreens Prescription Savings Club
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.